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Summary. The hypothetical capacity of amphotericin B to suppress the formation of germ-tubes, which is the first step of 
yeast-to-hypha conversion in Candida albicans, has been investigated in the wild-type strain CEY.1 (CAI.4-URA+). Exponential 
cells exposed to concentrations of amphotericin B below or around the MIC90, exhibited a weak reduction in the percentage of 
human serum-induced germ-tube formation at 37ºC compared with a non-exposed control. However, the dimorphic transition 
was drastically suppressed after addition of potentially lethal doses of amphotericin B, which also caused severe cell killing. In 
contrast, an identical experimental approach carried out with the fungistatic compound 5-fluorocytosine had no significant 
effect on the level of the germ-tube formation. Together, these results strongly point to a close correlation between the fungi-
cidal action of amphotericin B and its ability to impair morphogenetic conversion in C. albicans. [Int Microbiol 2015; 
18(1):25-31]
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Introduction
 
Antifungal therapy is less developed than the antibacterial 
equivalent. However, the striking increase in morbidity and 
mortality caused by invasive mycosis, which mainly affects 
the human immunocompromised population, demands new 
effort in this pharmaceutical field [22,24,25]. Together with 
the development of safer, more potent and less toxic com-
pounds, another line of work involves improving the currently 
available arsenal of fungicidal antibiotics [1]. A good exam-
ple of this pursuit is the polyene macrolide amphotericin B 
(AmB). Since its discovery in the 1950s [20] AmB has been 
the predominant compound utilized in clinical practice for the 
treatment of systemic infections caused by species of Can-
dida, Aspergillus, Cryptococcus and many other pathogenic 
fungi. However, this extensive use has provoked some toxic 
side-effects (nephrotoxicity and hepatic damage, mainly), 
which have successfully been surmounted by new liposomal 
formulations, permitting its current extensive utilization 
against invasive candidiasis [13,19]. Interestingly, clinical re-
sistance to AmB remains extremely rare despite 50 years of 
use as a monotherapy [28].
Many clinical trials have taken as a target the polimorphic 
opportunistic yeast Candida albicans, which is still the most 
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prevalent fungal pathogen in humans, where it is responsible 
for mucosal and disseminated infections [7,19,22,25]. Fur-
thermore, the incidence of C. albicans infections in neonates 
and patients subjected to extensive surgery therapy, as well as 
nosocomical bloodstream candidemia, has increased noticea-
bly in the last two decades [7,19,22,24]. Several studies on 
C. albi cans suggest that AmB may exert a complex mode of 
action, interacting with different cellular targets. Although the 
specific binding to the membrane ergosterol triggers perturba-
tions in the selective membrane permeability that eventually 
lead to cell killing, the formation of pores and membrane in-
stability has been dissociated from the fungicidal effect [21]. 
Other evidences gathered in C. albicans and Cryptococcus neo-
formans [29] involve the generation of oxidative stress through 
the release of reactive oxygen species, would reinforce the fun-
gicidal effect of AmB-induced cell damage [4,6,9,16].
Candida albicans is a polimorphic organism able to grow 
as a unicellular budding yeast or as mycelial forms (hypha 
and pseudohypha). The morphological transition from yeast 
to hypha has been considered as a contributory factor of viru-
lence [10,15]. It has been proposed that exposure to AmB 
causes a dose-dependent severe reduction in the germ-tube 
development, which is the first step of hypha formation [8,26]. 
In fact, the success obtained with early therapies that used 
AmB to treat oral candidiasis seemed to involve a significant 
reduction in the percentage of germ-tube formation, which is 
the first step in the yeast-to-hypha conversion of this oppor-
tunistic pathogen [8]. Oral candidiasis remains among the 
main manifestations of mycosis caused by C. albicans, in-
cluding a great proportion of HIV-infected patients [18]. 
However, such observations are far from conclusive [7,24,25]. 
We have examined this suggestion in a prototypic wild-type 
C. albicans URA3+ strain, by testing putative effects on di-
morphism and cell viability triggered by the polyene AmB 
and the fungistatic antibiotic 5-fluorocytosine (5-FC), a py-
rimidine analogue that interferes with DNA synthesis by re-
ducing the available nucleotide pool [12]. Our rationale was 
to try to dissociate morphological inhibition from killing cell 
processes. According to our data, the blockage of germ-tube 
development seems to be a direct consequence of the previous 
drastic fungicidal action of AmB. 
Material and methods
Yeast strains and culture conditions. Because an ura3 auxotrophy 
might have side effects on the physiology and virulence of C. albicans, a 
CEY.1 (CAI4-URA3+) strain was used throughout this study. A detailed de-
scription of the constructions and procedures followed to obtain this strain is 
reported elsewhere [23]. This same strain has been used in previous research 
on the antifungal action of AmB [11]. Yeast cell cultures were grown at 28ºC. 
They were shaken in a medium consisting of 2% peptone, 1% yeast extract 
and 2% glucose (YPD). Strains were maintained by periodic subculturing in 
solid YPD. 
Human-serum induction of germ tube formation. For germ-tube 
induction, cultures were either directly supplemented with 10% human blood 
serum or, alternatively, samples were harvested at different stages of growth, 
quickly washed with water and resuspended at a density of 1–5 ×106 cells/ml 
in YPD prewarmed to 37ºC together with 10% human serum. Before addi-
tion, serum was sterilized by filtration (0.45 mm). The appearance of germ 
tubes was monitored as indicated by phase contrast light microscope with a 
haemocytometer. When required, clumped cells were dispersed prior to mi-
croscopic examination by mild sonication (10–15 s). At least 250 cells were 
counted each time and the percentage of dimorphism was represented as the 
ratio of germ tube-forming cells to the total number of cells [3,23].
AmB and 5-FC treatments. AmB was obtained from Sigma (80% pu-
rity) and prepared in DMSO (100%). It was then maintained at room tempera-
ture for autosterilisation, since it is not possible to filter the compound. Be-
cause the solutions are all very light-sensitive, they were manipulated in dark 
conditions. 5-FC was also from Sigma, and was dissolved in MiliQ water.
Cultures were grown in YPD until the exponential phase (OD600 = 0.3) 
and then divided into several identical aliquots, which were treated with differ-
ent concentrations of AmB or 5-FC and incubated at 28ºC with shaking. The 
samples were harvested at the indicated times and viability was determined 
after appropriate dilution of the samples with sterile water by plating in tripli-
cate on solid YPD. Between 30 and 300 colonies were counted per plate. Sur-
vival was normalized to control non-treated samples (100% viability).
MICs determination. The MIC90 for AmB and 5-FC against CEY.1 
(URA3+) cells was determined according to a normalized protocol for yeasts 
(EUCAST with minor modifications). Briefly, a microtiter plate (96 wells) 
(Brand 781660, Wertheim, Germany) was filled with 100 µl of different con-
centrations of AmB (0.0125; 0.025; 0.05; 0.1; 0.2; 0.4; 0.8; 1.6; 3.2; 6.4 and 
12.8 mg/ml) in RPMI 1640 medium plus 2% glucose buffered at pH 7.0 with 
MOPS 0.164 M. One hundred ml of a yeast suspension in sterile saline solu-
tion (105 cells/ml) was added to each well. The plates were incubated at 35°C 
for 24 h and 48 h and read at 550 nm on a microtiter reading instrument (Asys 
Jupiter). In accordance with the EUCAST protocol, the strain Candida par-
apsilosis ATCC 22019 has been included as quality control. The MIC was 
defined as the lowest concentration which inhibited 90% of the cell growth.
Results
Effects of AmB treatments on germ-tube for-
mation and cell killing in the C. albicans CEY.1 
(URA) strain. In a set of preliminary experiments, we have 
determined the MIC90 values for CEY.1 (CAI.4-URA3
+) cells 
against AmB and 5-FC. They were 0.12 and 0.25 mg/l, res-
pectively. The quality control required by the EUCAST pro-
cedure was included to ensure the validity of the calculations. 
These concentrations are within the range previously reported 
for other C. albicans genetic backgrounds of clinical or labo-
ratory origin [8].
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Fig. 1. Effect of rising concentrations of amphotericin B (AmB) on the time-course of germ-tube formation induced by human serum 
(A), the percentage of survival (B) and the microscopic cell morphologies (C and D) in the wild type strain CEY.1 (CAI-4 URA+) of 
C. albicans. The cultures were incubated at 28ºC in YPD until early exponential phase (OD = 0.3), harvested, washed and resus-
pended at a cellular density of 2 × 106 cells/ml in YPD supplemented with 10% human serum and immediately transferred at 37ºC. 
Identical samples were supplemented at time zero with the following doses of AmB (mg/l): 0 (control, ♦), 0.05 (■); 0.1 (▲); 0.5 (●) 
and 1.0 (ÿ). Error bars are omitted for the sake of clarity, but the standard deviation was always lower than 12%. (A and B). Serum-
induced samples were photographed after 5 h of treatment with 0.05 mg/l (C) or 0.5 mg/l (D) AmB.
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The addition of 10% human serum together with a tem-
perature up-shift from 28 to 37ºC has been demonstrated as an 
efficient procedure for inducing filamentation in C. albicans 
[3,11,23]. This was also the case for the wild-type strain 
CEY.1 (CAI.4-URA+). Exponentially-growing yeast cells 
(blastoconidia) in a glucose-rich medium (YPD) are fully 
competent to enter the dimorphic program when they are 
transferred to the same medium prewarmed at 37ºC, supple-
mented with human serum and further incubated at 37ºC (Fig. 
1A). It has been postulated that sub-lethal concentrations of 
AmB induce a complete suppression of the capacity to issue 
germ-tubes [8,26]. In the present study, the effect of several 
doses of AmB on the degree of human serum-induced initial 
filamentation in CEY.1 growing cells was studied. As shown 
in Figure 1A, the addition of AmB doses below or about the 
MIC90 value had a negligible effect on the level of germ-tube 
formation (about 10% reduction at 0.1 mg/l AmB; Fig. 1A). It 
was necessary to increase the AmB concentration to poten-
tially lethal levels (0.5 or 1.0 mg/l) in order to bring about a 
significant decay of mycelial outgrowth in comparison with a 
control sample maintained at 37ºC (Fig. 1A).
In equivalent cell aliquots withdrawn from the same cul-
tures, the effect of those selected AmB doses on the degree of 
cell killing was analyzed. The time-course percentage of via-
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Fig. 2. Reversible action of AmB on human serum-induced germ-tube formation (A) and cell viability 
(B) in C. albicans CEY.1 strain. An exponential culture growing on YPD at 28ºC was divided into identi-
cal aliquots, which were quickly supplemented with 10% human serum and transferred to 37ºC. Then, 
they were subjected to the following treatments: addition of 0.5 mg/l AmB for 30 min (■) or 60 min (▲) 
followed by rapid washing out AmB and resuspension in YPD plus human serum (time zero). Alterna-
tively, control samples were kept without AmB (♦) or with that toxic concentration of AmB throughout 
the assay (●). More details in Figure 1.
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ble CEY.1 blastoconidia underwent a minor reduction upon 
the addition of tolerated concentrations of AmB (ca. 20% at 
0.05 mg/l and 40% at 0.1 mg/l) (Fig. 1B), whereas fungicidal 
doses of the polyene (4 × MIC90 and 8 × MIC90) caused a more 
drastic and progressive loss of viable cells (Fig. 1B). Optical 
examination of samples treated for 1 h with 0.05 mg/l AmB 
showed normal serum-induced germ-tube emergence (Fig. 
1C), whereas a 10-fold increase in the AmB concentration 
(0.5 mg/l) completely prevented the dimorphic transition 
(Fig. 1D). Hence, these data strongly suggest that the suppres-
sive action on germ-tubes emergence in C. albicans after 
AmB supply might likely be an off-side indirect action de-
rived from its intrinsic fungicidal power rather than a direct 
target. Interestingly, AmB triggers a conspicuous individual 
reduction of cell size in yeast cultures [11].
In order to confirm this putative relationship between the 
antifungal power and suppression of hypha formation exerted 
by AmB, the following experiment was carried out. Growing 
CEY.1 blastoconidia were adjusted to a similar cell density 
(2x106 cells/ml) and preincubated with a toxic concentration 
of AmB (0.5 mg/l) for 30 or 60 min. Then, the antifungal was 
removed by washing the cells, which were quickly resuspend-
ed in human serum (10%) at 37ºC at an identical cell density. 
The degree of germ-tube development and the percentage of 
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Fig. 3. Level of dimorphic conversion (A) and cell growth (B) in CEY.1 cells induced by several concentrations of 
the fungistatic antibiotic 5-fluorocytosine (5-FC). A growing exponential culture was processed as indicated in the 
legend for Figure 2. Identical aliquots were treated with the following concentrations of 5-FC (mg/l): 0 (♦), 0.25 (●), 
1.0 (■) and 2.5 (▲). A sample containing 0.25 mg/l of AmB was introduced as control of the positive antifungal 
effect (ÿ). Error bars are omitted for the sake of clarity, but the standard deviation was always lower than 12%.
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cell survival were determined in parallel. According to the re-
sults presented in Figure 2, pretreatment with 0.5 mg/l AmB 
caused a time-dependent loss of viable cells (30 or 60 min) 
(Fig. 2B). Afterthat, however, the surviving fraction was still 
able to resume active grow to a certain extent as well as to 
enter the dimorphic program by producing conspicuous germ-
tubes (Fig. 2; results not shown). This dimorphic conversion 
markedly increased as the incubation period was prolonged 
(Fig. 2A). As expected, a sample subjected to the permanent 
presence of AmB lost its capacity to form germ-tubes, the re-
duction in cell viability being drastic and the subsequent level 
of survival extremely low (Fig. 2A and B). In turn, in a control 
culture treated with human serum at 37ºC, the degree of my-
celiation was higher than 80% after 2 h (Fig. 2A). In this set 
of experiments, a control sample was maintained at 37ºC 
without serum addition, and the level of germ-tube formation 
was about 10–20% (results not shown). 
Analysis of the action of 5-FC. The suppressive ac-
tion triggered by fungicidal exposure of AmB on the yeast-to-
hypha conversion capacity in C. albicans was also reinforced 
by studies carried out with the fungistatic compound 5-fluoro-
cytosine (5-FC). In exponential CEY-1 cells, the addition of 
concentrations around the MIC90 (0.25 mg/l) had no relevant 
effect on the percentage of filamentation or cell viability (Fig. 
3A and 3B). A moderate increase (4 × MIC90) in the dose of 
5-FC only caused a partial and sustained decrease in the level 
of survival and had an irrelevant effect on dimorphic conver-
sion, which was manifested by the rather similar ability to 
produce germ-tubes (Fig. 3B). The effect of 5-FC was not 
dose-dependent, since an additional rise (10 × MIC90) only 
caused a weak additional decrease in the level of survival and 
the percentage of germ-tube formation (Fig. 3). In this assay, 
an aliquot exposed to a lower concentration of AmB (0.25 
mg/l) was introduced as a positive control of the fungicidal 
action. As expected, the polyene provoked a severe degree of 
cell killing and, simultaneously, a pronounced inhibition in 
the ability to issue germ tubes (Fig. 3). 
Discussion
The morphological conversion from yeast cells (blastoconidia) 
to mycelial structures (hypha and/or pseudohypha) in C. albi-
cans has been considered a factor of virulence, although the 
matter is open to dispute [10]. The genetic evidence is not 
entirely conclusive: whereas some mutants unable to filament 
are avirulent [15], homozygous null mutants deficient in the 
MAP kinase HOG1 and in the transcriptional repressor factor 
TUP1 show a phenotype of hyperfilamentation but lack infec-
tivity in a murine model for systemic candidiasis [2,5]. Fur-
thermore, in other dimorphic fungi with great incidence in 
pathogenesis, e.g. Histoplasma capsulatum or Blastomyces 
dermatitidis, yeast-like cells instead of mycelia are the pre-
dominant invasive morphology in clinical mycoses [10]. 
These fungi are very susceptible to both AmB and azoles 
[13,14]. In turn, Candida glabrata, which displays high clini-
cal incidence due to its inherent resistance towards usual anti-
fungals, shows a typical growth as oval yeast cells [17].
In this context, a strong and inhibitory action of the poly-
ene AmB on the ability to produce germ-tubes in C. albicans 
has been proposed [8,26], although the mechanism for this 
suggested targeted inhibition remains unknown. However, the 
evidence provided in this study seems to dismiss this proposal 
and strongly points to the fungicidal action triggered by AmB 
as the main cause of the reduced formation of germ tubes in 
C. albicans. Thus, exponential blastoconida of the wild type 
CEY.1 strain (URA+) did not show significant loss of cell 
growth upon addition of sublethal concentrations of AmB 
(Fig. 1B) and were able to enter the dimorphic program, issu-
ing conspicuous germ tubes (Fig. 1A and 1C), although with a 
certain delay compared to the untreated samples (Fig. 1A). 
Only the treatment with toxic doses of AmB impeded the for-
mation of evident mycelial structures (Fig. 1D), probably due 
to the halt in cell growth (Fig. 1B).
On the other hand, these harmful effects on cell growth 
and hypha formation are reversible, conditioned to the pres-
ence of the antifungal in the culture broth. When a 4 × MIC90 
concentration of AmB was applied for a short time (30 or 60 
min) and then quickly removed from the medium, the cells 
suffered an initial decay in cell survival with no production of 
germ-tubes as long as the antifungal was present (Fig. 2). But, 
afterwards, they were able to resume active growth (Fig. 2B) 
and showed a capacity to undergo a noticeable dimorphic 
transition, which had remained unaffected during the transi-
tory exposure to AmB (Fig. 2A). Similar experiments per-
formed with the fungistatic 5-FC provided equivalent results 
and confirmed the validity of this proposal (Fig. 3).
The relationship between fungicidal action and hypha for-
mation might be relevant for clinical therapeutical purposes, 
particularly in the light of the ability of C. albicans to develop 
biofilms as a main pathogenesis mechanism [27]. Laboratory 
studies have proven that C. albicans biofilms have high intrin-
sic resistance to several antifungals, including polyenes, 
5-fluorocytosine (5-FC) and azoles [27], although they still 
remain susceptible to the application of echinocandins and 
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some lipid preparations of AmB, in the range of doses com-
monly used in clinical assays. Because fungal biofilms are 
heterogeneous communities of blastospores, pseudohyphal 
and hyphal cells embedded in an extracellular complex ma-
trix, experiments on the susceptibility of each population to 
AmB should be performed to clarify this matter. In conclu-
sion, we exclude yeast-to-hypha conversion as the main target 
of AmB. Rather, early AmB-induced germ-tube inhibition 
seems to be a side effect derived from the drastic lytic action 
of the polyene on cell integrity. 
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